Huberman Lab
Essentials: Psychedelics for Treating Mental Disorders | Dr. Matthew Johnson
· Summarized
Key takeaways
- Psychedelics can significantly alter perception and self-identity, providing therapeutic benefits in controlled environments.
- Neurobiology of psychedelics primarily involves interaction with serotonin receptors, impacting emotional and psychological states.
- Clinical trials support the efficacy of psychedelics in treating depression and PTSD.
- Microdosing lacks robust clinical evidence to validate claims of enhanced mood and cognition.
- Risks with psychedelics exist, especially regarding bad trips and unsuitable candidates, underscoring the need for careful administration.
- Future research on psychedelics may reveal further therapeutic benefits, especially for neurological health.
Summary
Introduction to Psychedelics and Their Classes
In this episode, Andrew Huberman interviews Dr. Matthew Johnson, who provides an overview of different classes of psychedelics, including classic psychedelics like LSD and psilocybin, hallucinogens, NMDA antagonists like ketamine, and MDMA. They discuss the challenges of categorizing psychedelics, emphasizing the diverse effects they have on perception and the sense of self.
The Neurobiology Behind Psychedelics
Dr. Johnson explains how psychedelics primarily interact with the serotonin system in the brain, specifically targeting serotonin receptors. This interaction is believed to profoundly alter individuals' perceptions of reality and self. The discussion also touches on the difference between serotonergic compounds and dopaminergic compounds like MDMA, highlighting how these differences affect emotional experiences.
Therapeutic Applications and Clinical Trials
The podcast delves into the potential therapeutic uses of psychedelics. Dr. Johnson discusses clinical trials demonstrating psychedelics' effectiveness in treating conditions like depression and PTSD. He mentions the importance of a safe and controlled environment for these experiences to mitigate risks like bad trips.
Microdosing: Myths and Realities
Questions surrounding microdosing psychedelics are addressed, including its claimed benefits for mental health and cognitive enhancement. Dr. Johnson shares skepticism regarding the efficacy of microdosing, emphasizing the lack of substantial clinical evidence to support these claims.
Risks and Considerations with Psychedelics
A significant part of the conversation is dedicated to discussing the risks associated with psychedelics, particularly for individuals with serious psychiatric conditions. Dr. Johnson highlights the potential for bad trips and emphasizes the importance of proper supervision and a supportive therapeutic environment.
The Future of Psychedelic Research
The podcast concludes with an exploration of the future of psychedelic research, including potential benefits for neurological injuries. Dr. Johnson expresses hope for ongoing studies evaluating the cognitive enhancements possible with psychedelics in patients with brain injuries.
Sponsors
- AG1 · AG1 is a vitamin mineral probiotic drink that also includes prebiotics and adaptogens. It improves overall health, energy focus, and digestive health.
- David · David makes a protein bar with 28 grams of protein, only 150 calories, and zero grams of sugar. It satisfies protein goals without excess calories.
- BetterHelp · BetterHelp offers professional therapy with licensed therapists entirely online, making it easy and efficient to get support.
Show notes
In this Huberman Lab Essentials episode, my guest is Dr. Matthew Johnson, PhD, a senior researcher for the Center of Excellence for Psilocybin Research and Treatment at Sheppard Pratt’s Institute for Advanced Diagnostics and Therapeutics.
We explore the science and therapeutic potential of psychedelic medicine, including psilocybin, MDMA and LSD. We discuss how these substances can profoundly alter perception and self-identity, providing long-lasting relief from depression, addiction and trauma when used in controlled clinical settings. We also discuss microdosing and emerging research on psychedelics’ potential to support recovery from neurological injuries.
Read the episode show notes at hubermanlab.com.
Thank you to our sponsors
AG1: https://drinkag1.com/huberman
David: https://davidprotein.com/huberman
BetterHelp: https://betterhelp.com/huberman
Timestamps
00:00:00 Matthew Johnson; Psychedelics
00:01:44 Different Classes of Psychedelics
00:04:33 Psychedelics & Altering Models
00:06:18 Sponsor: David
00:07:33 LSD, Psylocibin & Serotonin
00:09:55 Psychedelic Clinical Trials
00:13:40 Therapy, Trust, Psychedelics
00:16:47 Letting Go & Psychedelic Experience, Self-Representation, Lasting Changes
00:22:31 Sponsors: AG1 & BetterHelp
00:25:26 MDMA, Dopamine & Serotonin; Bad Trips & Transcendental Experience
00:28:49 Dangers of Psychedelics
00:31:11 Microdosing Psychedelics, Antidepressant
00:35:27 Head Injuries, Psychedelics, Depression
00:38:29 Acknowledgements
Disclaimer & Disclosures
Learn more about your ad choices. Visit megaphone.fm/adchoices
Follow this show on AudioBrevity and new episodes get summarized for you. Create a free account